Insulin enhances glucose-stimulated insulin secretion in healthy humans. 2010

Clara Bouche, and Ximena Lopez, and Amy Fleischman, and Aaron M Cypess, and Sheila O'Shea, and Darko Stefanovski, and Richard N Bergman, and Eduard Rogatsky, and Daniel T Stein, and C Ronald Kahn, and Rohit N Kulkarni, and Allison B Goldfine
Cellular and Molecular Physiology, Joslin Diabetes Center, Boston, MA 02215, USA.

Islet beta-cells express both insulin receptors and insulin-signaling proteins. Recent evidence from rodents in vivo and from islets isolated from rodents or humans suggests that the insulin signaling pathway is physiologically important for glucose sensing. We evaluated whether insulin regulates beta-cell function in healthy humans in vivo. Glucose-induced insulin secretion was assessed in healthy humans following 4-h saline (low insulin/sham clamp) or isoglycemic-hyperinsulinemic (high insulin) clamps using B28-Asp insulin that could be immunologically distinguished from endogenous insulin. Insulin and C-peptide clearance were evaluated to understand the impact of hyperinsulinemia on estimates of beta-cell function. Preexposure to exogenous insulin increased the endogenous insulin secretory response to glucose by approximately 40%. C-peptide response also increased, although not to the level predicted by insulin. Insulin clearance was not saturated at hyperinsulinemia, but metabolic clearance of C-peptide, assessed by infusion of stable isotope-labeled C-peptide, increased modestly during hyperinsulinemic clamp. These studies demonstrate that insulin potentiates glucose-stimulated insulin secretion in vivo in healthy humans. In addition, hyperinsulinemia increases C-peptide clearance, which may lead to modest underestimation of beta-cell secretory response when using these methods during prolonged dynamic testing.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D006728 Hormones Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various ENDOCRINE GLANDS and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects. Hormone,Hormone Receptor Agonists,Agonists, Hormone Receptor,Receptor Agonists, Hormone

Related Publications

Clara Bouche, and Ximena Lopez, and Amy Fleischman, and Aaron M Cypess, and Sheila O'Shea, and Darko Stefanovski, and Richard N Bergman, and Eduard Rogatsky, and Daniel T Stein, and C Ronald Kahn, and Rohit N Kulkarni, and Allison B Goldfine
September 2010, Diabetes,
Clara Bouche, and Ximena Lopez, and Amy Fleischman, and Aaron M Cypess, and Sheila O'Shea, and Darko Stefanovski, and Richard N Bergman, and Eduard Rogatsky, and Daniel T Stein, and C Ronald Kahn, and Rohit N Kulkarni, and Allison B Goldfine
December 2011, The Journal of clinical endocrinology and metabolism,
Clara Bouche, and Ximena Lopez, and Amy Fleischman, and Aaron M Cypess, and Sheila O'Shea, and Darko Stefanovski, and Richard N Bergman, and Eduard Rogatsky, and Daniel T Stein, and C Ronald Kahn, and Rohit N Kulkarni, and Allison B Goldfine
March 2018, The Journal of endocrinology,
Clara Bouche, and Ximena Lopez, and Amy Fleischman, and Aaron M Cypess, and Sheila O'Shea, and Darko Stefanovski, and Richard N Bergman, and Eduard Rogatsky, and Daniel T Stein, and C Ronald Kahn, and Rohit N Kulkarni, and Allison B Goldfine
February 2012, Diabetes,
Clara Bouche, and Ximena Lopez, and Amy Fleischman, and Aaron M Cypess, and Sheila O'Shea, and Darko Stefanovski, and Richard N Bergman, and Eduard Rogatsky, and Daniel T Stein, and C Ronald Kahn, and Rohit N Kulkarni, and Allison B Goldfine
January 2023, Plants (Basel, Switzerland),
Clara Bouche, and Ximena Lopez, and Amy Fleischman, and Aaron M Cypess, and Sheila O'Shea, and Darko Stefanovski, and Richard N Bergman, and Eduard Rogatsky, and Daniel T Stein, and C Ronald Kahn, and Rohit N Kulkarni, and Allison B Goldfine
March 1996, European journal of endocrinology,
Clara Bouche, and Ximena Lopez, and Amy Fleischman, and Aaron M Cypess, and Sheila O'Shea, and Darko Stefanovski, and Richard N Bergman, and Eduard Rogatsky, and Daniel T Stein, and C Ronald Kahn, and Rohit N Kulkarni, and Allison B Goldfine
March 2022, Metabolism: clinical and experimental,
Clara Bouche, and Ximena Lopez, and Amy Fleischman, and Aaron M Cypess, and Sheila O'Shea, and Darko Stefanovski, and Richard N Bergman, and Eduard Rogatsky, and Daniel T Stein, and C Ronald Kahn, and Rohit N Kulkarni, and Allison B Goldfine
November 1997, Hypertension (Dallas, Tex. : 1979),
Clara Bouche, and Ximena Lopez, and Amy Fleischman, and Aaron M Cypess, and Sheila O'Shea, and Darko Stefanovski, and Richard N Bergman, and Eduard Rogatsky, and Daniel T Stein, and C Ronald Kahn, and Rohit N Kulkarni, and Allison B Goldfine
July 2022, Diabetology international,
Clara Bouche, and Ximena Lopez, and Amy Fleischman, and Aaron M Cypess, and Sheila O'Shea, and Darko Stefanovski, and Richard N Bergman, and Eduard Rogatsky, and Daniel T Stein, and C Ronald Kahn, and Rohit N Kulkarni, and Allison B Goldfine
April 2008, Biological & pharmaceutical bulletin,
Copied contents to your clipboard!